No Data
Shandong Xinhua Pharmaceutical Announces December EGM
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Multiple bullish factors boost pharmaceutical stocks listed in Hong Kong, institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
Shandong Xinhua Pharmaceutical (00719.HK) subsidiary's Febuxostat Tablets obtained the pharmaceutical registration certificate, suitable for the long-term treatment of hyperuricemia with symptoms of gout.
On November 11, Gelonhui reported that Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) recently announced that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd. (hereinafter referred to as "Xinda Pharmaceutical") has received the Drug Registration Certificate for the generic drug Non-Bu Si Ta Tablets (hereinafter referred to as "this product") issued by the National Medical Products Administration, and approved the application for marketing authorization of this product. In June 2023, Xinda Pharmaceutical submitted the application materials for the registration and marketing authorization of Non-Bu Si Ta Tablets to the Center for Drug Evaluation (CDE) of the National Medical Products Administration and was accepted. In November 2024, it obtained the Drug Registration Certificate, with the evaluation conclusion: batch.
Express News | Shandong Xinhua Pharmaceutical: Nifedipine Tablets Obtained Pharmaceutical Registration Certificate
No Data
No Data